002630 — Orient Bio Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Orient Bio, fiscal year end - March 31st, KRW millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-15,275	34,198	-12,424	12,871	-13,195
Depreciation
Amortisation
Non-Cash Items	19,153	-33,942	-4,384	-13,141	11,613
Discontinued Operations
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	170	-1,830	14,878	1,343	380
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	8,739	2,351	1,160	3,757	752
Capital Expenditures	-256	-2,211	-486	-925	-4,789
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-3,777	18,981	-20,172	-2,191	5,104
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-4,033	16,770	-20,658	-3,116	316
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	3,875	-1,134	-6,792	-570	-840
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	8,590	19,052	-24,058	175	423